Navigation Links
D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI
Date:12/31/2009

REHOVOT, Israel, December 31 /PRNewswire-FirstCall/ -- D-Pharm Ltd (TASE: DPRM) announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).

The MACSI study is as international, multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial. The trial will compare the stroke outcome in a group of patients treated with placebo (an inactive substance) to patients treated with 1 mg/kg/day of DP-b99 for 4 consecutive days. The study is expected to enroll, in total, 770 patients at 120 - 140 clinical sites worldwide.

Recently D-Pharm met with the FDA to discuss the Special Protocol Assessment (SPA) and will continue the dialog with the FDA towards the final agreement.

Dr. Gilad Rosenberg, D-Pharm's V.P. Clinical Development stated, "We're very pleased that this important clinical milestone has been achieved on schedule. The challenge is now to effectively activate the additional clinical sites to ensure a patient recruitment rate sufficient to complete the study on time, as planned."

For the global development of DP-b99, D-Pharm Ltd. will collaborate with its partners Yungjin Pharmaceuticals in S. Korea and Wanbang Biopharmaceuticals in China. Stroke is a leading cause of serious long-term disability and the second most common cause of death worldwide. The number of acute ischemic stroke patients in the US, Western Europe and Japan is around 1.5 million; including the territories of S. Korea and China may almost double this figure.

About DP-b99


'/>"/>

SOURCE D-Pharm Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
2. D-Pharm Secures Funding From Israels Chief Scientists Office
3. D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Reportlinker.com announces that a new market ... Global Chelating Agents Market 2014-2018 ... Agent A chelating agent is a chemical substance ... thereby forming a metal-ion complex. It reduces the ... processes, formulations, and the environment by chelating with ...
(Date:8/27/2014)... 27, 2014  A novel biomarker for rheumatoid ... better identify early-stage disease, when treatment can often ... a new study in The Journal of Rheumatology. ... DGX ) and other institutions found that ... conventional antibody-serum testing, including rheumatoid factor (RF) and ...
(Date:8/27/2014)... LONDON , Aug. 27, 2014 ... The Graphene Opportunity - A Rational ... Is Graphene The New Nanotech? A similar ... predictions of applications ranging from microelectronics to water ... today announced the availability of the Graphene Opportunity ...
(Date:8/27/2014)... -- Research and Markets  has announced the addition ... Industry Report 2014" report to their offering. ... Industry Report 2014 is a professional and in-depth study ... mass spectrometer industry. The report provides a ... and industry chain structure. The isotope ratio mass spectrometer ...
Breaking Biology Technology:Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 2Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 3Novel Biomarker Detects Early Rheumatoid Arthritis Better than Conventional Methods Alone, According to Journal of Rheumatology Study 4The Graphene Opportunity - A Rational View 2The Graphene Opportunity - A Rational View 3The Graphene Opportunity - A Rational View 4Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2
... . Most people value large chunks of gold ... gold at the smallest possible scale, because single gold atoms are ... atoms are placed on a surface they tend to ball up ... scientists now managed to fix single gold atoms on special sites ...
... May 30, 2012  Luminex Corporation (NASDAQ: LMNX ... Jefferies 2012 Global Healthcare Conference to be held June ... ) The investor presentation by Patrick J. ... 1:30 p.m. Eastern time on Wednesday, June 6, 2012.  The ...
... Inc. (Nasdaq: AUXL ) today announced that executive ... to be held June 4-7, 2012 at the Grand Hyatt ... and President, is scheduled to present an overview of the ... Monday, June 4, 2012. A breakout session will be held ...
Cached Biology Technology:The finest gold dust in the world 2Luminex Corporation to Present at Jefferies 2012 Global Healthcare Conference 2Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 2Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 3Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference 4
(Date:8/27/2014)... of the human genome was unveiled today in the ... comparison yet of how the genomes of the fruit ... appearing August 28 in in the journal Nature ... species, genomes is "read out," and how their DNA ... add billions of entries to a publicly available archive ...
(Date:8/27/2014)... be getting effective doses of the HIV drug maraviroc, ... dosing studies, completed before the drug was licensed in ... that is key to removing maraviroc from the body. ... of the protein including nearly half of African-Americans ... compared to those who lack the protein even when ...
(Date:8/27/2014)... SALT LAKE CITY, Aug. 27, 2014 University of ... in his native Turkey, has won that nation,s highest ... Medal of Science. , Sekercioglu is among five researchers ... Scientific and Technical Research Council of Turkey. Three researchers ... won the Special Award, which is equivalent to ...
Breaking Biology News(10 mins):Encyclopedia of how genomes function gets much bigger 2Encyclopedia of how genomes function gets much bigger 3Encyclopedia of how genomes function gets much bigger 4Dosage of HIV drug may be ineffective for half of African-Americans 2University of Utah biologist wins Turkey's top science prize 2
... levels of greenhouse gases, particularly carbon dioxide (CO2), ... fuels, deforestation, cultivation of grasslands, drainage of the ... shifts in climate patterns have led scientists to ... and to develop methods to evaluate how changes ...
... On Monday 4 February, Dennis J. Selkoe and five other ... Leuven. The promoters for this honorary doctorate VIB-KU Leuven ... Dennis J. Selkoe for his scientific insights, but also for ... and other conditions that cause severe damage in the brain. ...
... RayBiotech, Inc. announced today that it has executed ... Institute (BSHRI) of Sun City, Arizona.  Under the terms ... the biochemical analysis of disease markers in biological samples.  ... the characterization of key biomarkers for the study of ...
Cached Biology News:New protocol recommendations for measuring soil organic carbon sequestration 2New protocol recommendations for measuring soil organic carbon sequestration 3New protocol recommendations for measuring soil organic carbon sequestration 4Prevention is better than cure. Also for Alzheimer's disease! 2Prevention is better than cure. Also for Alzheimer's disease! 3Prevention is better than cure. Also for Alzheimer's disease! 4RayBiotech, Inc. Executes Neuroscience Biomarker Master Services Agreement with Banner Sun Health Research Institute 2RayBiotech, Inc. Executes Neuroscience Biomarker Master Services Agreement with Banner Sun Health Research Institute 3
... Situ Assay Kit is a fluorescent-based assay ... undergoing apoptosis. The kit is for research ... or therapeutic procedures. CHEMICON®s CaspaTag™ Pan-Caspase In ... to detect active caspases. The methodology is ...
... INTERFERin is a new-generation siRNA transfection ... efficiency at 1 nM siRNA in a ... with excellent cell viability. Using low siRNA ... effects observed when transfecting siRNA at higher ...
... R&D Systems Cell and Tissue Staining Kits ... a broad range of histological and cytological ... primary IgG antibodies manufactured by either R&D ... is based on the formation of the ...
... measurements in an easy-to-use benchtop package. ... spectrometer (ESI-oa-TOF) concentrates the performance of ... which fits on your bench. The ... 10,000 FWHM and mass accuracy of ...
Biology Products: